Originally from Zagreb, Croatia, Filip obtained his PhD in neuroscience at the University of Minnesota, USA. His doctoral work focused on investigating neuropeptide substrates of Angiotensin-converting enzyme using mass spectrometry, and in parallel, drug development for substance use disorders. In November 2025, Filip joined the Ðikić group as a postdoctoral fellow. His postdoctoral work is focused on ProxiDrug development using mass spectrometry proteomics.